ema semaglutide naion label update 2025 Your diabetic patient on develops NAION. Do you stop the drug?, The ( European Medicines Agency) says yes — in June it labeled a very rare side effect of semaglutide and A potentially blinding condition is

Tirzepatide: The First GLP-1/GIP Dual Agonist Tirzepatide is a dual incretin agonist that activates both the glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors and was developed to enhance metabolic and weight-loss outcomes beyond those achieved with GLP-1 receptor agonists alone

Best for: patients who want flexibility between branded and compounded medication

How Eligibility Decisions Work at Willow Willow ties eligibility decisions to a specific sequence: account creation leads to an intake form, and eligibility is evaluated only after that intake is submitted for external clinician review

On a standard detachable needle insulin syringe, this dead space can be 0.05-0.08 ml

Peak effects occur within 30 to 90 minutes